Abstract Purpose The aim of this study was to investigate the effect of oral administration of a combination of alpha- lipoic acid (ALA) and myo-inositol (Myo) on serum and endometrial inflammation of women with unexplained recurrent pregnancy loss (uRPL). Methods Serum and endometrial levels of Nacht leucine-rich-repeat protein-3 (NLRP-3) and High Mobility Group Box 1 (HMGB-1) were analyzed by ELISA in women with unexplained Recurrent Pregnancy Loss (uRPL) (n = 31) and in control women who had had at least one uncomplicated pregnancy at term (n = 10) before and after daily oral administration of a commercial combination of ALA and Myo. Results uRPL women had higher serum levels (p < 0.01) and endometrial content (p < 0.0001) of HMGB-1 than controls while no difference was observed regarding NALP3. Oral administration of ALA and Myo for three months significantly decreased pre-treatment serum levels of NLRP-3 (p < 0.0001) and HMGB-1 (p < 0.0001), as well as endometrial content of NLRP-3 (p < 0.001) and HMGB-1 (p < 0.0001) in uRPL women, similar to those found in controls. Conclusion Women with uRPL have increased systemic and endometrial inflammation than controls. Oral administration of ALA and Myo could modulate serum and endometrial levels of NLRP-3 and HMGB-1 in uRPL women.
Tersigni et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: